Because of the translational requirement of SPORE research, it is essential that SPORE investigators haveaccess to and assistance with animal models for therapeutic hypothesis testing. The UCSF Brain TumorSPORE Animal Core will address this need by utilizing serially-passaged human GBM xenografts inconducting in vivo studies using immune-deficient mice and rats.Emphasis will be placed on the use of serially-passaged xenografts since our cumulative experience withthis system of tumor propagation indicates that serial in vivo passaging promotes tumor retention of keyproperties that are lost during cell line establishment. In additon, the Animal Core will emphasize orthotopic(intracranial) therapeutic testing because intracranial tumors established from serially propagated flankxenografts are highly invasive, and therefore present a more rigorous and clinically-relevant test oftherapeutic efficacy than would be provided by the well-circumscribed subcutaneous tumors propagated inthe flanks of nude mice, or by well-circumscribed intracranial tumors that are produced by injection ofestablished cell lines. In association with this test model philosophy, the objectives of the UCSF Brain TumorAnimal Core are as follows:
Aim 1 : Propagate, analyze (histopathological and molecular), archive, and maintain up-to-date records on all GBM xenografts used in support of SPORE animal model research.
Aim 2 : Coordinate and conduct all immune deficient rodent therapeutics testing, including optical imaging and molecular analyses of intracranial xenograft specimens, in assessing tumor response to therapy.
Aim 3 : In association with the Tissue and Outcome Core, utilize xenograft resources to facilitate interpretation of results from immunohistochemical and FISH analysis of therapeutic targets and/or surrogate markers in patient tumors.
Aim 4 : Collect, process, and distribute, within and outside of UCSF, xenograft tumor tissues and tissue extracts, so as to promote intra- and inter-SPORE collaborations, and utilization of these renewable tumor resources.
Showing the most recent 10 out of 362 publications
